Literature DB >> 6353626

Characterization of cell surface antigens of human mammary epithelial cells with monoclonal antibodies prepared against human milk fat globule.

R L Ceriani, J A Peterson, J Y Lee, R Moncada, E W Blank.   

Abstract

Hybridomas have been prepared that secrete monoclonal antibodies against three different surface antigens of normal human mammary epithelial cells by fusion of mouse myeloma cells with spleen cells from mice and rats immunized with delipidated human milk fat globules. Using a novel method for molecular weight determination, the three different monoclonal antibodies, BLMRL-HMFG-Mc3, BLMRL-HMFG-McR2, and BLMRL-HMFG-Mc5, were found to identify molecules with apparent molecular weights of 46,000, 70,000, and 400,000 daltons, respectively. The latter is a mucin-like glycoprotein with a high sugar content and has not previously been described as a component of the human milk fat globule or of human mammary epithelial cell membranes. Single-cell quantitation of binding of monoclonal BLMRL-HMFG-Mc5 to three breast tumor cell lines using a Microscope Spectrum Analyzer and indirect immunofluorescence revealed a heterogeneous expression. Further, using a competitive radioimmunoassay, it was found that breast tumor cell lines differed by at least 10-fold in the 400,000-molecular-weight antigen content. None of the three antigens are detectable on several nonbreast cell lines, including normal breast fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353626     DOI: 10.1007/bf01543043

Source DB:  PubMed          Journal:  Somatic Cell Genet        ISSN: 0098-0366


  24 in total

1.  Immunophenotype of SV40-T gene transfected epithelial cell lines derived from human benign breast tumors.

Authors:  H Raux; P Planchon; F Chraibi-Hajji; V Magnien; V Sallé; D Brouty-Boyé
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

2.  Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection.

Authors:  R R McNeer; D Huang; N L Fregien; K L Carraway
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  Localization of human breast tumors grafted in nude mice with a monoclonal antibody directed against a defined cell surface antigen of human mammary epithelial cells.

Authors:  R L Ceriani; M Sasaki; D Orthendahl; L Kaufman
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

4.  Localization of a membrane glycoprotein in benign fibrocystic disease and infiltrating duct carcinomas of the human breast with the use of a monoclonal antibody to guinea pig milk fat globule membrane.

Authors:  D E Greenwalt; V G Johnson; F P Kuhajda; J C Eggleston; I H Mather
Journal:  Am J Pathol       Date:  1985-03       Impact factor: 4.307

5.  Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies.

Authors:  R Mesa-Tejada; R B Palakodety; J A Leon; A O Khatcherian; C J Greaton
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

Review 6.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

7.  Breast epithelial antigen levels and breast tumor antigen content.

Authors:  R L Ceriani; C Chan
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

8.  A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity.

Authors:  W Z Wei; R J Massey; G H Heppner
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  Epitope expression on the breast epithelial mucin.

Authors:  R L Ceriani; J A Peterson; E W Blank; D T Lamport
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts.

Authors:  L Ozzello; C M De Rosa; E W Blank; K Cantell; R L Ceriani; D V Habif
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.